Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT)
Status:
Terminated
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if adding low dose Thalidomide
(thalidomide) to Revlimid (lenalidomide) maintenance therapy will help control MM after an
autologous stem cell transplant. Researchers also want to learn if treatment with these study
drugs will improve participants' quality of life.